New shot aims to keep rare kidney diseases in check
NCT ID NCT07499700
First seen Apr 10, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study tests an injection called BAT4406F in 192 adults with two rare kidney diseases (MCD or FSGS) that cause protein leakage and swelling. The goal is to see if the drug can reduce protein in urine and prevent relapses better than a placebo. Participants must have responded to steroids in the past and will be followed for up to a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL CHANGE DISEASE (MCD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.